Vaxcyte, Inc.

Vaxcyte, Inc. is a U.S.-based biotechnology company developing protein-based vaccines, with a primary focus on pneumococcal conjugate vaccine candidates. Its pipeline also includes other preclinical vaccine programs built on a cell-free protein synthesis platform, and its work is centered on research, development, and outsourced manufacturing rather than internal commercial production.

7.91

7.91

— Vaxcyte, Inc.
%
Pneumococcal conjugate vaccines (PCVs)80% Conjugate vaccine candidates designed to prevent pneumococcal disease across adult and pediatric populations.
Other prophylactic vaccine candidates10% Preclinical vaccine programs targeting infectious diseases such as Group A Strep and Shigella.
Cell-free manufacturing platform10% Proprietary platform used to produce vaccine components and enable scalable conjugate vaccine manufacturing.

Vaxcyte does not sell commercial products today; its end customers are future vaccine purchasers such as healthcare...

  • Future adult vaccine marketprimary

    Would buy PCV products for adult immunization against pneumococcal disease if approved.

  • Future pediatric vaccine marketprimary

    Would buy PCV products for infant and child immunization programs if approved.

  • Clinical development partnerssecondary

    CROs, clinical sites, and investigators that execute trials and generate data.

  • Manufacturing partnersprimary

    CMOs such as Lonza and Thermo Fisher that supply drug substance, extract, and fill-finish.

  • Academic and government collaboratorssecondary

    Universities and NIH-supported partners that help advance early-stage programs.

Vaxcyte is headquartered in the United States and its development and manufacturing network is centered in the U.S...

  • •Headquartered in the United States
  • •Commercial planning is centered on the U.S. market
  • •Manufacturing relies on Lonza and Thermo Fisher facilities
  • •Supply chain includes U.S. and international third-party partners
  • •Future vaccine launches are intended for global commercialization

Vaxcyte’s strategy is to advance broad-spectrum pneumococcal vaccine candidates toward regulatory approval while...

01
Advance PCV franchise to commercializationshort-term

PCV candidates are the core value driver and the most advanced programs.

02
Scale manufacturing and fill-finish capacityshort-term

Commercial viability depends on reliable, high-quality vaccine supply at scale.

03
Maintain platform and IP controlmedium-term

Control over cell-free extract and conjugate methods supports differentiation and supply security.

04
Preserve optionality in non-PCV programsmedium-term

Early-stage programs can expand the pipeline without distracting from the lead franchise.

Vaxcyte faces the typical risks of a clinical-stage biotech company: uncertain trial outcomes, regulatory delays, and...

high

Clinical development failure or delay

Lead candidates must show safety, tolerability, and efficacy before approval.

Scope
VAX-31, VAX-24, VAX-XL, VAX-A1, VAX-GI
Materiality
high
high

Third-party manufacturing dependence

The company does not own commercial manufacturing facilities and relies on CMOs.

Scope
Lonza, Thermo Fisher, Sutro-related supply chain
Materiality
high
high

Funding and dilution risk

Development and commercialization require substantial additional capital.

Scope
Equity and other external financing
Materiality
high
high

Regulatory and approval risk

Vaccine candidates may face delays or requests for additional data from agencies.

Scope
U.S. and global vaccine approvals
Materiality
high
medium

Public perception of vaccines

Negative sentiment can affect trial enrollment, adoption, and approval dynamics.

Scope
Vaccine category broadly
Materiality
medium
Accrued research and development expenses
Can shift expenses between periods and affect comparability
Stock-based compensation
Affects operating loss and per-share metrics
Lease accounting
Affects balance sheet leverage and operating expense presentation
Impairment of development-related assets and rights
Could create non-cash charges if projects lose value

PharmaCyte Biotech, Inc.

PMCB · Biological Products, (No Diagnostic Substances)

INCYTE CORP

INCY · Services-Commercial Physical & Biological Research

New Wave

NEWA-B.ST · Consumer Discretionary

Bufab

BUFAB.ST · Industrials

Apotea

APOTEA.ST · Consumer Staples

Fabege

FABG.ST · Real Estate

: 29.4.2026